Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Longboard Pharmaceuticals (LBPH) has provided an announcement.
Longboard Pharmaceuticals has revealed promising interim results from their PACIFIC OLE Study on bexicaserin, a treatment for Developmental and Epileptic Encephalopathies, showcasing a significant reduction in motor seizure frequency. This 52-week safety study also demonstrated favorable safety and tolerability profiles. As a result, Longboard is actively planning a global Phase 3 program, with further presentations on the study anticipated at upcoming medical meetings. Investors and analysts are keenly observing as these developments may signal a pivotal advancement in the treatment of these complex conditions, potentially positioning Longboard as a notable player in the pharmaceutical industry.
See more data about LBPH stock on TipRanks’ Stock Analysis page.